What are your plans for Easter break?
We're looking forward to spending time with loved ones and soaking up some sun.
To family and our friends, happy holidays and enjoy the next few days!
Across Markets…
As its entry into the psychedelic medicine space progresses, Creso Pharma (ASX: CPH) has continued its cannabinoid product focus with the launch of three CBD-based tea products.
The company has unveiled three CBD-based teas which will be sold under its cannaQIX brand. These products are based on Creso’s second generation technology that optimises CBD taste and content and comprise: cannaQIX tea, cannaQIX NITE tea and cannaQIX Immunity tea.
According to Creso, cannaQIX tea was designed to help stress management and support better life quality, while cannaQIX NITE tea is to be drunk at night to support better sleep, and cannaQIX Immunity contains supplements to optimise well-being.
Creso describes its new CBD-based teas as a “ground breaking” technological achievement that provides the company with a “significant competitive advantage”.
Source: Small Caps
China stocks rose on Thursday, led by consumer and healthcare shares, even as investors appeared to have shrugged off a survey showing weaker-than-expected factory activity growth in the world’s second-largest economy.
The CSI300 index was up 0.6% at 5,079.97 points by the end of the morning session, while the Shanghai Composite Index gained 0.3% to 3,450.36 points.
The Hang Seng index added 1.1% to 28,699.85 points, while the Hong Kong China Enterprises Index gained 1.4% to 11,122.59.
Around the region, MSCI’s Asia ex-Japan stock index was firmer by 0.78% while Japan’s Nikkei index was up 0.64%.
The yuan was quoted at 6.5686 per U.S. dollar, 0.26% weaker than the previous close of 6.5518.
Source: Reuters
Sector: Consumer Discretionary
Deal Type: Placement
Raise Amount: $2.2m
Latest Entry Price: $0.006 with a 1:4 DW8O
Today's Price Change: $0.165 +6.45%
Sector: Gaming & Digital Advertising
Deal Type: Placement
Raise Amount: $1.25m
Latest Entry Price: $0.02 with a 1:1 ICIOB
Today's Price Change: $0.105 +5.00%
Sector: Fintech
Deal Type: Placement
Raise Amount: $1.5m
Latest Entry Price: $0.015 with a 1:2 option
Today's Price Change: $0.10 Unchanged
Sector: Biopharma
Deal Type: IPO Cornerstone
Raise Amount: $1m+
Latest Entry Price: $0.35
Today's Price Change: $2.64 +2.72%
Sector: Satellite Communication
Deal Type: Placement
Raise Amount: $5m
Latest Entry Price: $0.25 with a 1:3 Option
Today's Price Change: $0.275 +3.77%
Sector: Vertical Farming
Deal Type: Placement
Raise Amount: $1.53m
Latest Entry Price: $0.05 with a 2:3 Option
Today's Price Change: $0.054 Unchanged
Sector: Consumer Discretionary
Deal Type: Seed, Bridging and IPO
Raise Amount: $10m
Latest Entry Price: $0.08 with a 1:1 CLBO
Sector: Hemp & CBD
Deal Type: Pre IPO
Raise Amount: $2.5m
Latest Entry Price: $0.20
Today's Price Change: CAD $0.28 +1.79%
Sector: Psychedelic assisted Therapy
Deal Type: Pre IPO
Raise Amount: $1.5m
Latest Entry Price: $0.08 with a 1:2 Option
Today's Price Change: CAD $0.17 Unchanged
Sector: mining
Deal Type: Placements & Rights Offer
Raise Amount: $1.5m
Latest Entry Price: $0.013 with a 1:1 MRQOC
Today's Price Change: $0.01 -5.00%
Sector: CBD
Raise Amount: $5M
Latest Entry Price: $0.022 with a 1:2 AVEO
Today's Price Change: $0.022 Unchanged
Sector: Industrials
Deal Type: Placement
Raise Amount: $750k
Latest Entry Price: $0.015
Today's Price Change: $0.022 -4.35%
Company: 8Common Ltd (ASX:8CO)
Sector: Information Technology
Deal Type: Placement
Raise Amount: $800k
Latest Entry Price: $0.03 with a 1:1 Option
Today's Price Change: $0.23 Unchanged
Sector: Mining (Gold)
Deal Type: Placement
Raise Amount: $982k
Latest Entry Price: $0.0115 with a 1:1 SBRO
Today's Price Change: $0.005 -9.09%
Sector: Mining (Gold/Silver)
Deal Type: Placement
Raise Amount: $2.3m
Latest Entry Price: $0.014 with a 1:1 GEDO
Today's Price Change: $0.011 +10.00%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
